Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by V. Adonkina
Pcn180 - Pharmacoeconomic Assessment of Fulvestrant Versus Dd (Doxorubicin, Docetaxel) Therapy in Postmenopausal Women With Metastatic Er (+) Her2 (-) Breast Cancer in Ukraine
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pharmacoeconomic Grounding of Using Polypill Amlodipine With Atorvastatin Versus Monodrugs in Patients With Hypertension and Dyslipidemia in Ukraine
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Quantitative ER and PgR Assessment as Predictors of Benefit From Lapatinib in Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Pharmacoeconomic Analysis of Docetaxel in the Adjuvant Therapy of Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
HER2-Orientated Therapy in Early and Metastatic Breast Cancer
Breast Care
Surgery
Oncology
Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
Oncologist
Cancer Research
Medicine
Oncology
Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Correction To: Unexpected Benefit From Alpelisib and Fulvestrant in a Woman With Highly Pre-Treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
Clinical Drug Investigation
Medicine
Pharmacology
Extended Adjuvant Therapy With Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial
Clinical Cancer Research
Cancer Research
Oncology
